ProMetic Life Sciences Inc. (TSE:PLI) will be posting its quarterly earnings results after the market closes on Monday, November 13th.

ProMetic Life Sciences Inc. (PLI) opened at C$1.40 on Friday. ProMetic Life Sciences Inc. has a twelve month low of C$1.12 and a twelve month high of C$2.92.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/10/prometic-life-sciences-inc-pli-set-to-announce-quarterly-earnings-on-monday.html.

A number of equities analysts recently commented on the company. Royal Bank Of Canada decreased their target price on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a report on Wednesday, August 16th. TD Securities decreased their price objective on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a report on Wednesday, August 16th. Finally, National Bank Financial increased their price objective on ProMetic Life Sciences from C$2.00 to C$2.50 in a report on Wednesday, August 30th.

In other news, Director Dwun-Hou Chen sold 32,321 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of C$1.14, for a total value of C$36,845.94. Also, insider Bruce Pritchard sold 84,594 shares of ProMetic Life Sciences stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of C$1.15, for a total value of C$97,283.10. Over the last ninety days, insiders have purchased 184,150 shares of company stock worth $231,429 and have sold 388,397 shares worth $507,577.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.